Candel Therapeutics, Inc.

NASDAQ:CADL

Biotechnology

Healthcare
$5.32 +0.56%

+$0.05 today

Market cap
$417.33M
Beta
-0.48
P/E (TTM)
-9.2
EPS (TTM)
-$0.87
52W Low $4.35High $9.57

Volume 1.39M

Average 1.82M

CADL Purchases of Investments

Cash used to buy marketable securities and other investments.

Candel Therapeutics, Inc.NASDAQ: CADL

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments outflow grows to $0

Q1 FY2026 purchases of investments was $0, compared with $0 a year earlier. Trailing-twelve-month purchases of investments was $0.

Context

  • Purchases of investments increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly purchases of investments holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Purchases of Investments vs competitors

How CADL compares with its peers on the latest reported figures

  • Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
CADL Competitors
Purchases of Investments for CADL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$432.32M USD+24.6%+9.0%114.1%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$413.13M USD+104.3%+18.9%—
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$224.66M USD-43.9%-26.6%103.4%
MGNXMacroGenics, Inc.LTM Mar 2026$202.4M USD+485.0%+20.0%128.9%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$171.05M USD+72.2%-41.4%—
PBYIPuma Biotechnology, Inc.LTM Mar 2026$120.5M USD+89.0%+181.7%53.0%
GNLXGenelux CorporationLTM Mar 2026$30.2M USD+6.7%—377475.0%
IMMXImmix Biopharma, Inc.LTM Mar 2026$14.25M USD———
NBPNovaBridge BiosciencesLTM Sep 2025CN¥171.53K CNY—-81.1%—
CADLCandel Therapeutics, Inc.LTM Mar 2026$0 USD———
Peer median (excluding CADL) —+72.2%+9.0%114.1%

Competitors are the stored peer set for CADL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(36.12M)(18.79M)(37.94M)(55.18M)(38.18M)
Depreciation & Amortization232K778K1.28M990K845K
Deferred Income Tax11.51M0000
Stock-Based Compensation2.96M2.31M3.09M5.31M3.82M
Change in Working Capital(876K)71K(378K)346K2.19M
Accounts Receivables00000
Inventory00000
Accounts Payables669K(1.21M)45K(185K)802K
Other Working Capital(1.55M)1.28M(378K)531K1.39M
Other Non-Cash Items76K(15.78M)(301K)21.51M(6.98M)
Operating Cash Flow(22.22M)(31.42M)(34.24M)(27.02M)(38.31M)
Capital Expenditures(1.84M)(1.3M)(457K)(16K)(587K)
Acquisitions (Net)000027K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00177K00
Investing Cash Flow(1.84M)(1.3M)(280K)(16K)(560K)
Debt Repayment019.91M0(9.17M)36.21M
Common Stock Issued71.34M00101.76M19.89M
Common Stock Repurchased00(121K)00
Dividends Paid00000
Other Financing Activities465K64K01.69M0
Financing Cash Flow71.8M19.97M(121K)94.28M56.1M
Effect of Forex Changes00000
Net Change in Cash47.75M(12.74M)(34.65M)67.24M17.23M
Free Cash Flow(24.05M)(32.72M)(34.7M)(27.04M)(38.9M)

Candel Therapeutics, Inc.

NASDAQ:CADL

Intrinsic Alpha fair value

Locked

Current Price

$5.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.